Anthem Biosciences FY26 Profit Rises 32.5% to INR 6,705.64 Million

Anthem Biosciences Limited has announced its audited financial results for the fiscal year ended March 31, 2026. The company reported a standalone net profit of INR 6,705.64 million for the year, marking a 32.5% increase from INR 5,061.88 million in the previous year. Revenue from operations for the year stood at INR 20,893.12 million, compared to INR 18,406.49 million in FY25.

For the quarter ended March 31, 2026, the company recorded a standalone net profit of INR 2,116.65 million. Revenue from operations for the quarter was INR 5,825.01 million. The Board approved the audited standalone and consolidated financial results prepared in accordance with the Indian Accounting Standards (Ind-AS).

Dividend Declaration

The Board of Directors recommended a final dividend of INR 2.00 per equity share of face value INR 2.00 each for the financial year ended March 31, 2026. This dividend is subject to the approval of shareholders at the ensuing Annual General Meeting. The record date for the purpose of determining eligibility has been fixed as Friday, June 26, 2026.

Corporate Actions

The Board approved the allotment of 14,81,250 equity shares to eligible employees upon exercise of options under the Anthem Employee Stock Option Plan 2024. Consequently, the paid-up equity share capital has increased to INR 1,12,63,90,202. Additionally, the Board approved convening the 20th Annual General Meeting on Wednesday, July 22, 2026.

The Board also recommended the continuation of Mr. Ravikant Uppal as a Non-Executive Independent Director and the re-appointment of Mr. Ravindra Chandrappa as Whole Time Director, subject to shareholder approval.

Key Financials (Standalone) Year Ended Mar 31, 2026 Year Ended Mar 31, 2025 Total Income INR 22,713.87 million INR 19,500.89 million Total Expenses INR 13,443.04 million INR 12,386.66 million Net Profit INR 6,705.64 million INR 5,061.88 million Basic EPS INR 11.95 INR 9.05

The statutory auditors, M/s. K. P. Rao & Co., issued an unmodified opinion on the audited standalone and consolidated financial results. The company also re-appointed M/s. BPU & Co. as internal auditors for the financial year 2026-2027.

Anthem Biosciences Limited has announced its audited consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported its highest revenue quarter ever in Q4FY26, driven by strong performance across its CRDMO and Specialty Ingredients segments.

Q4FY26 Financial Performance

For the quarter ended March 31, 2026, the company reported Revenue from Operations of ₹6,109 Mn, a growth of 26.4% compared to ₹4,832 Mn in the same period last year. The CRDMO segment contributed ₹5,128 Mn, while Specialty Ingredients contributed ₹981 Mn. Profit After Tax (PAT) for the quarter surged 129.8% to ₹1,898 Mn from ₹826 Mn in Q4FY25. EBITDA stood at ₹3,184 Mn, with margins expanding to 48.1% from 40.38% in the same period last year.

The following table summarises Anthem Biosciences' key financial metrics for Q4FY26:

Metric (₹ Mn) Q4FY26 Q4FY25 YoY Growth Revenue from Operations 6,109 4,832 26.4% EBITDA 3,184 2,092 52.2% EBITDA Margin 48.1% 40.38% — Profit After Tax 1,898 826 129.8%

FY26 Annual Results

For the full financial year 2025-26, Revenue from Operations grew 15.2% to ₹21,243 Mn from ₹18,446 Mn in FY25. The CRDMO business recorded revenues of ₹17,727 Mn, and Specialty Ingredients recorded ₹3,516 Mn. PAT for the year increased 31.1% to ₹5,918 Mn, while EBITDA grew 30.8% to ₹9,896 Mn. The company maintained a healthy net cash position of ₹13,743 Mn as of March 31, 2026.

Metric (₹ Mn) FY26 FY25 YoY Growth Revenue from Operations 21,243 18,446 15.2% EBITDA 9,896 7,566 30.8% Profit After Tax 5,918 4,513 31.1% Net Cash Position 13,743 — —

Operational Highlights

The company's EBITDA and PAT for the year grew by more than 30%, in line with its growth aspirations. Management attributed the performance to prudent cost management and a focus on long-term value creation. Anthem Biosciences continues to invest in expanding its manufacturing capacity, including a new greenfield facility at Harohalli, Bangalore, with a Phase I investment of ₹12,000 Mn.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.